Smith & Nephew (LSE:SN.) - Aktienkurs, Nachrichten und Analyse

SN. Aktienübersicht

Smith & Nephew plc entwickelt, fertigt, vermarktet und verkauft zusammen mit seinen Tochtergesellschaften medizinische Geräte und Dienstleistungen im Vereinigten Königreich und auf internationaler Ebene.

Über das Unternehmen

SN. fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	2/6
Financial Health	4/6
Dividends	3/6

Belohnungen

35.6% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 21.56% pro Jahr

Analysten sind sich einig, dass der Aktienkurs um 31%

Risikoanalyse

Die Dividende von 3.01% ist nicht ausreichend durch Gewinne oder Cashflows gedeckt.

Hat einen hohen Schuldenstand

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Smith & Nephew plc Wettbewerber

NIOX Group

AIM:NIOX

UK£290.9m

ConvaTec Group

LSE:CTEC

UK£5.1b

EKF Diagnostics Holdings

AIM:EKF

UK£131.4m

Mediclinic International

LSE:MDC

UK£3.7b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Smith & Nephew
Historical stock prices
Current Share Price	UK£10.16
52 Week High	UK£12.69
52 Week Low	UK£8.87
Beta	0.57
1 Month Change	0.89%
3 Month Change	-6.28%
1 Year Change	-18.70%
3 Year Change	-34.46%
5 Year Change	-40.60%
Change since IPO	5,023.41%

Aktuelle Nachrichten und Updates

Smith & Nephew plc (LON:SN.) Not Flying Under The Radar

Apr 16

Recent updates

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 11

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Aug 19

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Jul 17

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Jun 11

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

May 09

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Apr 09

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

Feb 09

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

Nov 21

Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)

Nov 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price

Oct 26

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well

Aug 11

There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital

Jul 28

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 26

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Apr 29

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Safely

Mar 26

Earnings Beat: Smith & Nephew plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 24

Smith & Nephew's (LON:SN.) Returns On Capital Not Reflecting Well On The Business

Jan 25

Aktionärsrenditen

	SN.	GB Medical Equipment	GB Markt
7D	-1.2%	-0.08%	-0.6%
1Y	-18.7%	-9.0%	5.4%

Rendite im Vergleich zur Industrie: SN. unter dem Niveau der Branche UK Medical Equipment, die im vergangenen Jahr eine Rendite von -9.2% erzielte.

Rendite vs. Markt: SN. hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 7 erzielte.

Preisvolatilität

Is SN.'s price volatile compared to industry and market?
SN. volatility
SN. Average Weekly Movement	2.8%
Medical Equipment Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	2.8%

Stabiler Aktienkurs: SN. hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: SN.Die wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1856	18,452	Deepak Nath	www.smith-nephew.com

Smith & Nephew plc entwickelt, produziert, vermarktet und verkauft zusammen mit seinen Tochtergesellschaften medizinische Geräte und Dienstleistungen im Vereinigten Königreich und international. Das Unternehmen ist in drei Segmenten tätig: Orthopädie, Sportmedizin und HNO sowie erweiterte Wundversorgung. Das Unternehmen bietet Knieimplantate für Kniegelenkersatzverfahren, Hüftimplantate für Revisionsverfahren, Trauma- und Extremitätenprodukte, die interne und externe Vorrichtungen zur Stabilisierung schwerer Frakturen und Deformationskorrekturverfahren umfassen, sowie andere Rekonstruktionsprodukte.

Smith & Nephew plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Smith & Nephew im Vergleich zum Marktanteil des Unternehmens?
SN. grundlegende Statistiken
Marktanteil	UK£8.79b
Gewinn(TTM)	UK£205.51m
Umsatz(TTM)	UK£4.34b

43.1x

Kurs-Gewinn-Verhältnis

2.0x

Kurs-Umsatz-Verhältnis

Ist SN. zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
SN. Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$5.55b
Kosten der Einnahmen	US$1.66b
Bruttogewinn	US$3.89b
Sonstige Ausgaben	US$3.63b
Umsatz	US$263.00m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

Aug 01, 2024

Gewinn per Aktie (EPS)	0.30
Bruttomarge	70.14%
Nettogewinnspanne	4.74%
Schulden/Eigenkapital-Verhältnis	55.3%

Wie hat sich SN. auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

2.9%

Aktuelle Dividendenrendite

124%

Ausschüttungsquote

SN. Aktienübersicht

Belohnungen

Risikoanalyse

Smith & Nephew plc Wettbewerber

AIM:NIOX

UK£290.9m

LSE:CTEC

UK£5.1b

AIM:EKF

UK£131.4m

LSE:MDC

UK£3.7b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith & Nephew plc (LON:SN.) Not Flying Under The Radar

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

Recent updates

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith & Nephew plc (LON:SN.) Not Flying Under The Radar

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

Is Smith & Nephew plc (LON:SN.) Trading At A 30% Discount?

New minor risk - Earnings quality

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Consensus EPS estimates fall by 21%

Final dividend of US$0.23 announced

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Full year 2023 earnings: EPS misses analyst expectations

Capital Allocation Trends At Smith & Nephew (LON:SN.) Aren't Ideal

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Is Smith & Nephew plc (LON:SN.) Trading At A 36% Discount?

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Is Smith & Nephew (LON:SN.) Using Too Much Debt?

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew (LON:SN.) Could Be Struggling To Allocate Capital

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.0% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Consensus EPS estimates increase by 10%

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Now 22% undervalued

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Insider recently bought UK£117k worth of stock

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold UK£111k worth of stock

Consensus EPS estimates fall by 12%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

High number of new directors

CEO & Director exercised options to buy UK£59k worth of stock.

Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Upcoming dividend of US$0.14 per share

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Erträge & Einnahmen